Our independent approach has set us far ahead of other emerging research efforts in diabetes.

We’ve balanced the backing of prominent institutions with our own unwavering focus on the end goal: the simplest, most accessible cure. And we’ve been able to tailor our approach to an already-substantiated regulatory path.

NEWS

PIPELINES

PETS

PEOPLE

Progress in dogs

ENDSULIN has begun a pilot study in naturally diabetic companion dogs. We are the only group in the world testing gene therapy in large mammals for diabetes with an autoimmune disease.

Dogs are the Ideal preclinical model, because they are the largest animal model with autoimmune diabetes, and the etiology is nearly identical to human type 1 diabetes.

Running the trials in naturally diabetic family dogs rather than lab-induced canines also allows us to observe the treatment’s effects in a much more realistic situation.

Engineering

Optimization

Pre-clinical

Pilot

Pivotal

Progress in humans

Because of the similarities in dog and human diabetes, successful results in pets should be a strong indicator of how to optimize the human treatment.

Target ID

Pre-clinical

IND-enabling

Clinical trials

Foundational research

ENDSULIN has proven efficacy and durability in hundreds of rodents.

Dr. Sollinger’s research, conducted at UW-Madison, has been published in several peer-reviewed scientific research journals, including PLOS ONE in June 2013.

Read it now

This video shows two treated rats, an experimental control and an untreated rat (the smallest animal).

INCREDIBLE IMPACT

0 people
30 million people struggle with Type 1 diabetes in developed countries worldwide. It’s also one of the fastest-growing diseases.

Not only could this treatment realistically reach millions of patients with Type 1 diabetes — early signs show it could potentially treat Type 2 diabetes, too.

0 x
as many patients suffer with type 2 diabetes

2-4 insulin injections

every day, on average, to manage the disease. ►
Proper management takes constant monitoring and restrictive lifestyle changes.

Fewer than 2k patients

receive pancreas transplants each year, worldwide. ►
This procedure is the only long-term diabetes treatment available now, but there are limited donors available.

Leading cause

of kidney failure, blindness, and vascular disease. ►

Even with diligent daily management, many patients still experience severe complications.